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Nitric oxide (NO) is a signaling molecule that plays an important role in a variety of physiologic functions including vasodila-
tion, regulation of blood pressure, heart rate, renal function and gastrointestinal protection as well as being implicated in a 
number of pathophysiological conditions including inﬂammation and endothelial dysfunction. NO was originally identiﬁed as 
endothelium-derived relaxant factor (EDRF) based on the seminal observations of Furchgott and Zawadzki1 in 1980.  When 
a strip of rabbit aorta was isolated and incubated with acetylcholine, concentration-dependent tissue relaxation occurred only 
if the endothelial tissue remained intact. This observation led to the conjecture that there must exist an endothelium-deri-
ved relaxant factor (EDRF) and that this factor, EDRF, was required for vasodilation in vivo.1 Several years later, EDRF was 
identiﬁed as NO2,3 and in 1998, the Nobel Prize for Physiology or Medicine was awarded to Furchgott, Ignarro and Murad for 
discoveries concerning “nitric oxide as a signalling molecule in the cardiovascular system”4 and for their overall contributions 
to the ﬁeld of NO biology. It was not clear in the 1980’s, when these initial observations were made, how critical NO would be 
shown to be for a variety of signaling pathways. 
Over time, the role of NO as a crucial signaling molecule required to modulate cardiovascular and renal function, blood 
pressure, platelet activity, inﬂammation, gastrointestinal function, and apoptosis has been further elucidated.  New research 
has shown that the redox derivatives of NO, including peroxynitrite, are not simply toxic byproducts but play active roles in 
mediating cellular functions.  This entire area of investigation continues to provide an exciting target for therapeutic interven-
tion in a wide range of conditions including cardiovascular and inﬂammatory diseases. 
This supplement is based on a symposium that was held during the 2007 Osteoarthritis Research Society International 
World Congress on Osteoarthritis entitled “Nitric Oxide: From Basic Biology to Therapeutic Potential.” The goals of the sym-
posium were to discuss the chemistry of NO and to understand the molecular mechanisms underlying NO signaling and 
their effects on both cartilage and the cardiovascular system. The OARSI satellite symposium provided the opportunity for 
participants to gain an increased understanding of NO biology at the level of the joint and within the cardiovascular system. 
The presentations opened the dialogue on the potential for developing novel therapeutic approaches that may be beneﬁcial 
in the treatment of osteoarthritis. 
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